Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Operating and Financial Results
24 mars 2022 16h01 HE
|
Eledon Pharmaceuticals, Inc.
Topline data from Phase 2a trial of tegoprubart in ALS expected in 2Q 2022 Ongoing clinical studies evaluating tegoprubart in kidney transplantation, IgA nephropathy, and islet cell transplantation...
Travere Therapeutics Submits New Drug Application for Sparsentan for the Treatment of IgA Nephropathy
21 mars 2022 07h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration...
Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022
17 mars 2022 08h00 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Travere Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
24 févr. 2022 16h01 HE
|
Travere Therapeutics, Inc.
NDA submission of sparsentan in IgA nephropathy on-track for first quarter 2022 Company positioned for potential NDA submission for accelerated approval of sparsentan in FSGS and combined IgA...
Eledon Pharmaceuticals Provides Corporate Update and 2022 Outlook
14 févr. 2022 08h00 HE
|
Eledon Pharmaceuticals, Inc.
Completed enrollment of all four cohorts in ongoing Phase 2a study with tegoprubart (AT-1501) in Amyotrophic Lateral Sclerosis (ALS) Announces USAN Approval of Generic Name “tegoprubart” for lead...
Eledon Pharmaceuticals to Participate in 11th Annual SVB Leerink Global Healthcare Conference
08 févr. 2022 16h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Travere Therapeutics Provides Corporate Update and 2022 Outlook
10 janv. 2022 07h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for...
Travere Therapeutics to Present Abstracts at American Society of Nephrology Kidney Week 2021
02 nov. 2021 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present abstracts based on non-clinical data...
Travere Therapeutics Reports Third Quarter 2021 Financial Results and Organizational Progress
28 oct. 2021 16h01 HE
|
Travere Therapeutics, Inc.
Recently reported positive topline interim results from the ongoing pivotal Phase 3 PROTECT Study of sparsentan in IgA nephropathy Following pre-NDA interactions with FDA, NDA submission of...
Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
16 août 2021 07h00 HE
|
Travere Therapeutics, Inc.
Sparsentan treatment group experienced 49.8 percent mean reduction of proteinuria from baseline after 36 weeks, more than threefold the reduction of active comparator; interim primary efficacy...